Stock Research: Pfizer

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Pfizer

NYSE:PFE US7170811035
56
  • Value
    42
  • Growth
    8
  • Safety
    Safety
    100
  • Combined
    47
  • Sentiment
    57
  • 360° View
    360° View
    56
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. It operates in the oncology, primary care, and specialty care industries. Pfizer operates globally with a focus on the U.S. and international markets. In the last fiscal year, the company had a market cap of $139,917 million, profits of $47,295 million, revenue of $63,627 million, and 81000 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 56 (better than 56% compared with alternatives), overall professional sentiment and financial characteristics for the stock Pfizer are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Pfizer. The consolidated Value Rank has an attractive rank of 100, which means that the share price of Pfizer is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 100% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 57, which means that professional investors are more optimistic about the stock than for 57% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 8, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 42, meaning the company has a riskier financing structure than 58 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Dividends USA
Employee Focus US
D.J. US Pharmaceutical
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
100 96 96 99
Growth
8 11 1 89
Safety
Safety
42 33 91 41
Sentiment
57 48 14 44
360° View
360° View
56 86 51 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
9 18 15 27
Opinions Change
67 65 17 40
Pro Holdings
n/a 32 61 43
Market Pulse
83 79 41 82
Sentiment
57 48 14 44
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
100 96 96 99
Growth
8 11 1 89
Safety Safety
42 33 91 41
Combined
47 77 81 96
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
86 76 68 93
Price vs. Earnings (P/E)
49 47 37 46
Price vs. Book (P/B)
63 54 50 31
Dividend Yield
100 100 100 100
Value
100 96 96 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
8 22 28 61
Profit Growth
32 18 13 84
Capital Growth
21 21 19 25
Stock Returns
29 47 19 97
Growth
8 11 1 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
45 42 62 52
Refinancing
22 11 63 15
Liquidity
66 73 91 75
Safety Safety
42 33 91 41

Similar Stocks

Discover high‑ranked alternatives to Pfizer and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.